References
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2019. CA Cancer J Clin. 2019;69(1):7-34.
- Sung H, Ferlay J, Siegel RL, Laversanne M, Soerjomataram I, Jemal A, et al. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J Clin. 2021;71(3):209-49.
- Wojtyla C, Bertuccio P, Wojtyla A, La Vecchia C. European trends in breast cancer mortality, 1980-2017 and predictions to 2025. Eur J Cancer. 2021;152:4-17.
- Aggarwal S, Verma SS, Aggarwal S, Gupta SC. Drug repurposing for breast cancer therapy: Old weapon for new battle. Semin Cancer Biol. 2021;68:8-20.
- Harper JW, Adami GR, Wei N, Keyomarsi K, Elledge SJ. The p21 Cdk-interacting protein Cip1 is a potent inhibitor of G1 cyclin-dependent kinases. Cell. 1993;75(4):805-16.
- Whittaker SR, Mallinger A, Workman P, Clarke PA. Inhibitors of cyclin-dependent kinases as cancer therapeutics. Pharmacol Ther. 2017;173:83-105.
- Yarden Y, Elkabets M, editors. Resistance to Anti-Cancer Therapeutics Targeting Receptor Tyrosine Kinases and Downstream Pathways. Resistance to Targeted Anti-Cancer Therapeutics; 2018.
- Al Bitar S, Gali-Muhtasib H. The Role of the Cyclin Dependent Kinase Inhibitor p21(cip1/waf1) in Targeting Cancer: Molecular Mechanisms and Novel Therapeutics. Cancers (Basel). 2019;11(10).
- Deng T, Yan G, Song X, Xie L, Zhou Y, Li J, et al. Deubiquitylation and stabilization of p21 by USP11 is critical for cell-cycle progression and DNA damage responses. Proc Natl Acad Sci U S A. 2018;115(18):4678-83.
- Shamloo B, Usluer S. p21 in Cancer Research. Cancers (Basel). 2019;11(8).
- Suvarna KS LC, Bancroft JD, Editors. Bancroft’s Theory and Practice of Histological Techniques. 8th edition. Churchill Livingstone/Elsevier Science. 2018.
- Tan PH, Ellis I, Allison K, Brogi E, Fox SB, Lakhani S, et al. The 2019 World Health Organization classification of tumours of the breast. Histopathology. 2020;77(2): 181-5.
- Goldhirsch A, Wood WC, Coates AS, Gelber RD, Thurlimann B, Senn HJ. Strategies for subtypes-dealing with the diversity of breast cancer: highlights of the St. Gallen International Expert Consensus on the Primary Therapy of Early Breast Cancer 2011. Ann Oncol. 2011;22(8):1736-47.
- Allred DC, Harvey JM, Berardo M, Clark GM. Prognostic and predictive factors in breast cancer by immunohistochemical analysis. Mod Pathol. 1998;11(2):155-68.
- Wolff AC, Hammond ME, Hicks DG, Dowsett M, McShane LM, Allison KH, et al. Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. Arch Pathol Lab Med. 2014;138(2):241-56.
- Focke CM, Burger H, van Diest PJ, Finsterbusch K, Glaser D, Korsching E, et al. Interlaboratory variability of Ki67 staining in breast cancer. Eur J Cancer. 2017;84: 219-27.
- Gnant M, Thomssen C, Harbeck N. St. Gallen/Vienna 2015: A Brief Summary of the Consensus Discussion. Breast Care (Basel). 2015;10(2):124-30.
- Gimenez-Bastida JA, Avila-Galvez M, Espin JC, Gonzalez-Sarrias A. Conjugated Physiological Resveratrol Metabolites Induce Senescence in Breast Cancer Cells: Role of p53/p21 and p16/Rb Pathways, and ABC Transporters. Mol Nutr Food Res. 2019;63(22):e1900629.
- Kashyap D, Kaur H. Cell-free miRNAs as non-invasive biomarkers in breast cancer: Significance in early diagnosis and metastasis prediction. Life Sci. 2020;246: 117417.
- Feng Y, Spezia M, Huang S, Yuan C, Zeng Z, Zhang L, et al. Breast cancer development and progression: Risk factors, cancer stem cells, signaling pathways, genomics, and molecular pathogenesis. Genes Dis. 2018; 5(2):77-106.
- Aggarwal V, Kashyap D, Sak K, Tuli HS, Jain A, Chaudhary A, et al. Molecular Mechanisms of Action of Tocotrienols in Cancer: Recent Trends and Advancements. Int J Mol Sci. 2019;20(3).
- Zohny SF, Al-Malki AL, Zamzami MA, Choudhry H. p21(Waf1/Cip1): its paradoxical effect in the regulation of breast cancer. Breast Cancer. 2019;26(2):131-7.
- Wei CY, Tan QX, Zhu X, Qin QH, Zhu FB, Mo QG, et al. Expression of CDKN1A/p21 and TGFBR2 in breast cancer and their prognostic significance. Int J Clin Exp Pathol. 2015;8(11):14619-29.
- Jassim MMA, Rasool KH, Mahmood MM. p53, p21, and cyclin d1 protein expression patterns in patients with breast cancer. Vet World. 2021;14(10):2833-8.
- Zohny SF, Baothman OA, El-Shinawi M, Al-Malki AL, Zamzami MA, Choudhry H. The KIP/CIP family members p21^{Waf1/Cip1} and p57^{Kip2} as diagnostic markers for breast cancer. Cancer Biomark. 2017;18(4): 413-23.
- Barbareschi M, Caffo O, Doglioni C, Fina P, Marchetti A, Buttitta F, et al. p21WAF1 immunohistochemical expression in breast carcinoma: correlations with clinicopathological data, oestrogen receptor status, MIB1 expression, p53 gene and protein alterations and relapsefree survival. Br J Cancer. 1996;74(2):208-15.
- Bankfalvi A, Tory K, Kemper M, Breukelmann D, Cubick C, Poremba C, et al. Clinical relevance of immunohistochemical expression of p53-targeted gene products mdm-2, p21 and bcl-2 in breast carcinoma. Pathol Res Pract. 2000;196(7):489-501.
- Mansouri S, Esmaeili R, Kaviani A, Rezaei M, Abdoli N, Mokhtari-Hesari P, et al. The Interaction Between the Expression of Proliferative Biomarkers and Clinical Characteristics in Breast Cancer. Multidisciplinary Cancer Investigation. 2018;2(2):20-8.
- Balbin M, Hannon GJ, Pendas AM, Ferrando AA, Vizoso F, Fueyo A, et al. Functional analysis of a p21WAF1,CIP1,SDI1 mutant (Arg94 --> Trp) identified in a human breast carcinoma. Evidence that the mutation impairs the ability of p21 to inhibit cyclin-dependent kinases. J Biol Chem. 1996;271(26):15782-6.
- Bedir R, Gucer H, Sehitoglu I, Yurdakul C, Bagc? P, Ustuner P. The Role of p16, p21, p27, p53 and Ki-67 Expression in the Differential Diagnosis of Cutaneous Squamous Cell Carcinomas and Keratoacanthomas: An Immunohistochemical Study. Balkan Med J. 2016; 33(2):121-7.
- Caffo O, Doglioni C, Veronese S, Bonzanini M, Marchetti A, Buttitta F, et al. Prognostic value of p21(WAF1) and p53 expression in breast carcinoma: an immunohistochemical study in 261 patients with longterm follow-up. Clin Cancer Res. 1996;2(9):1591-9.
- Rey MJ, Fernandez PL, Jares P, Munoz M, Nadal A, Peiro N, et al. p21WAF1/Cip1 is associated with cyclin D1CCND1 expression and tubular differentiation but is independent of p53 overexpression in human breast carcinoma. J Pathol. 1998;184(3):265-71.
- Hermeking H, Funk JO, Reichert M, Ellwart JW, Eick D. Abrogation of p53-induced cell cycle arrest by c- Myc: evidence for an inhibitor of p21WAF1/CIP1/SDI1. Oncogene. 1995;11(7):1409-15.
- Lin D, Fiscella M, O'Connor PM, Jackman J, Chen M, Luo LL, et al. Constitutive expression of B-myb can bypass p53-induced Waf1/Cip1-mediated G1 arrest. Proc Natl Acad Sci U S A. 1994;91(21):10079-83.
- Barboule N, Baldin V, S JO, Vidal S, Valette A. Increased level of p21 in human ovarian tumors is associated with increased expression of cdk2, cyclin A and PCNA. Int J Cancer. 1998;76(6):891-6.
- Cai K, Dynlacht BD. Activity and nature of p21(WAF1) complexes during the cell cycle. Proc Natl Acad Sci U S A. 1998;95(21):12254-9.
- Brugarolas J, Bronson RT, Jacks T. p21 is a critical CDK2 regulator essential for proliferation control in Rbdeficient cells. J Cell Biol. 1998;141(2):503-14.
- Hiyama H, Iavarone A, LaBaer J, Reeves SA. Regulated ectopic expression of cyclin D1 induces transcriptional activation of the cdk inhibitor p21 gene without altering cell cycle progression. Oncogene. 1997;14(21):2533-42.
- Xia W, Chen JS, Zhou X, Sun PR, Lee DF, Liao Y, et al. Phosphorylation/cytoplasmic localization of p21Cip1/WAF1 is associated with HER2/neu overexpression and provides a novel combination predictor for poor prognosis in breast cancer patients. Clin Cancer Res. 2004; 10(11):3815-24.
- Diaz Flaque MC, Vicario R, Proietti CJ, Izzo F, Schillaci R, Elizalde PV. Progestin drives breast cancer growth by inducing p21(CIP1) expression through the assembly of a transcriptional complex among Stat3, progesterone receptor and ErbB-2. Steroids. 2013;78(6):559-67.
- Cheng X, Xia W, Yang JY, Hsu JL, Chou CK, Sun HL, et al. Activation of p21(CIP1/WAF1) in mammary epithelium accelerates mammary tumorigenesis and promotes lung metastasis. Biochem Biophys Res Commun. 2010;403(1):103-7.